Pilot Study of Somatostatin Receptor Imaging in Nasopharyngeal Cancer

Hypothesis: To estimate the proportion of locally advanced, recurrent or metastatic nasopharyngeal cancer patients which show high somatostatin receptor density (SUVmax >10) on Ga-68 DOTATATE imaging.

Galium-68 DOTATATE: PET imaging will be performed with a PET/CT scanner. Galium-68 DOTATATE will be injected intravenously. Scanning will be performed approximately 60 minutes after the injection.

The standardized uptake value (SUV) will be used in the interpretation of the Ga-68 DOTATATE scans. The values gathered will be used as an estimate of the somatostatin receptor density. A patient will be considered to have an overall high somatostatin receptor density if the average SUVmax of all the representative lesions is more than 10.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Nasopharyngeal Carcinoma Carcinoma Head and Neck Neoplasms Nasopharyngeal Diseases Nasopharyngeal Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial Otorhinolaryngologic Diseases Otorhinolaryngologic Neoplasms Pharyngeal Diseases Pharyngeal Neoplasms Stomatognathic Diseases

Age range

21 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

National Cancer Centre

Singapore, 169610

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Locally advanced NPC or Metastatic NPC or locally recurrent NPC
>21 years old
Histological confirmation of NPC

Exclusion criteria

<21 years old
Pregnancy or breast feeding

Treatment and study plan

Primary outcomes

Number of NPC patients with high somatostatin receptor density

Time frame: 60 minutes

High somatostatin receptor density is when average maximum standardized uptake value (SUVmax) of all the representative lesions is more than 10 on Ga-68 DOTATATE imaging

Sponsors and collaborators

Lead sponsor

National Cancer Centre, Singapore

Other

Collaborators

A*Star
Singapore General Hospital

Registry information

Important dates

Study start: 2015
Primary completion: 2019
Study completion: 2019
First posted: Sep 13, 2018
Registry last updated: Apr 30, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed